Profile data is unavailable for this security.
About the company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD-67.33k
- Incorporated2024
- Employees17.00
- LocationTevogen Bio Holdings Inc15 Independence Boulevard, Suite 410WARREN 07059United StatesUSA
- Phone+1 (646) 807-8832
- Fax+1 (302) 655-5049
More ▼
Mergers & acquisitions
| Acquired company | TVGN:NMQ since announced | Transaction value |
|---|---|---|
| Tevogen Bio Inc | -90.54% | 1.41bn |
Data delayed at least 15 minutes, as of May 13 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repare Therapeutics Inc | 97.86m | -45.69m | 148.56m | 179.00 | -- | 0.635 | -- | 1.52 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 150.68m | 126.00 | -- | 1.15 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 151.62m | 31.00 | -- | 2.49 | -- | 248.55 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 154.03m | 233.00 | -- | -- | -- | 1.21 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 154.28m | 120.00 | 10.01 | -- | 8.30 | 1.29 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 157.90m | 22.00 | -- | 3.19 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| ProQR Therapeutics NV | 14.53m | -28.91m | 161.08m | 157.00 | -- | 4.45 | -- | 11.09 | -0.3561 | -0.3561 | 0.1789 | 0.4451 | 0.0957 | -- | -- | 92,517.50 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Scpharmaceuticals Inc | 13.59m | -54.81m | 161.52m | 135.00 | -- | 4.33 | -- | 11.88 | -1.42 | -1.42 | 0.353 | 1.03 | 0.1243 | 0.7569 | -- | 100,688.90 | -50.13 | -38.23 | -55.33 | -42.31 | 71.96 | -- | -403.22 | -1,360.16 | 6.40 | -18.35 | 0.5105 | -- | -- | -- | -48.79 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 162.06m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Renovaro Inc | 0.00 | -41.23m | 162.35m | 12.00 | -- | 1.76 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 163.00m | 84.00 | -- | 7.51 | -- | 46.57 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Mediwound Ltd | 18.69m | -6.72m | 164.40m | 100.00 | -- | 5.06 | -- | 8.80 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Capricor Therapeutics Inc | 25.18m | -22.29m | 166.97m | 101.00 | -- | 7.30 | -- | 6.63 | -0.8708 | -0.8708 | 0.9403 | 0.7256 | 0.4627 | -- | 4.61 | 249,287.80 | -40.96 | -54.12 | -82.59 | -75.13 | -- | -- | -88.52 | -316.25 | -- | -- | 0.13 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Gossamer Bio Inc | 0.00 | -172.58m | 167.92m | 135.00 | -- | 6.28 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 172.67m | 147.00 | -- | -- | -- | 1.43 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| ASP Isotopes Inc | 433.03k | -16.29m | 176.12m | 76.00 | -- | 10.81 | -- | 406.72 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
Data as of May 13 2024. Currency figures normalised to Tevogen Bio Holdings Inc's reporting currency: US Dollar USD
4.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Portland Global Advisors LLCas of 31 Mar 2024 | 5.78m | 3.51% |
| Harraden Circle Investments LLCas of 10 Jan 2024 | 838.97k | 0.51% |
| Meteora Capital LLCas of 31 Dec 2023 | 505.67k | 0.31% |
| Glazer Capital LLCas of 31 Dec 2023 | 149.53k | 0.09% |
| Centiva Capital LPas of 31 Dec 2023 | 100.00k | 0.06% |
| Westchester Capital Management LLCas of 31 Dec 2023 | 99.95k | 0.06% |
| Koch Industries, Inc. (Investment Management)as of 31 Dec 2023 | 50.00k | 0.03% |
| Jackson National Asset Management LLCas of 31 Dec 2023 | 4.12k | 0.00% |
| Clear Street LLCas of 31 Dec 2023 | 600.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 30.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
